BRCA2 and cancer: We then asked if the loss of ENSG00000272172.1 might sensitize cancer cells to PARPi, similarly to the loss of BRCA1 or BRCA2. We therefore knocked down either BRCA1 or ENSG00000272172.1 and subsequently treated the cells with different doses of olaparib.